H4-CBD
H4CBD (Hydrogenated CBD, Tetrahydrocannibidiol), is a cannabinoid that was first synthesized by the Todd group in 1940 derived from the catalytic hydrogenation of cannabidiol. It's important to note that H4CBD, and H2-CBD and 8,9-Dihydrocannabidiol have also been referred to as "Hydrogenated CBD" which may cause confusion. Pharmacology 
In 2006, it was discovered that H4CBD has a binding affinity of 145nM at the CB1 receptor and potential anti-inflammatory effects independent of its cannabinoid receptor action. In contrast, CBD has been found to bind to the CB1 receptor as an inverse agonist/antagonist with a Ki ranging from 3.3 to 4.8 nM

Elucidation 
In 2023 H4CBD epimers were elucidated using NOESY, COSY, NMR spectroscopic techniques, while the inclusion of LC-MS and SCFC were used to isolate individual diasteromers. See also 
 H2-CBD (also hydrogenated CBD)
 8,9-Dihydrocannabidiol (one of the two components in H2CBD)
 Hexahydrocannabinol (hydrogenated THC)
 4'-Fluorocannabidiol
 7-Hydroxycannabidiol
 Abnormal cannabidiol
 Cannabidiol dimethyl ether
 Delta-6-cannabidiol

References 

Cannabinoids